| Name | Title | Contact Details |
|---|---|---|
Allison Frisbee |
Vice President, Assistant General Counsel | Profile |
Barbara Kosacz |
General Counsel | Profile |
Barbara Kosacz |
Chief Operating Officer and General Counsel | Profile |
Cypress Bioscience, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.